澳大利亚原住民成人重复接种肺炎球菌多糖疫苗与免疫反应性降低相关
研究评估澳大利亚北领地原住民成人首剂与第二剂23价肺炎球菌多糖疫苗(23vPPV)及非原住民成人首剂的免疫应答。原住民首剂应答 adequate 比例88%(53/60) vs 第二剂70%(14/20;p=0.05),两组差异未达统计学显著;非原住民首剂全部 adequate(25/25)。原住民首剂应答低于非原住民,第二剂后IgG更低,提示需评估重复接种方案。
要点
- 原住民成人首剂23vPPV后 adequate 应答88%(53/60),第二剂后70%(14/20),差异未达统计学显著(p=0.05)。
- 非原住民成人首剂23vPPV后全部 adequate(25/25)。
- 原住民首剂与非原住民首剂在≥70%和≥90%血清型阳性应答阈值上风险差显著。
核心结论
- 原住民成人对首剂23vPPV的应答差于非原住民成人,且第二剂后IgG更低。
- 研究结果强调需评估在推荐重复接种23vPPV的澳大利亚原住民人群中未来肺炎球菌疫苗项目的效力。
研究设计与样本
- 研究比较三组:接受第二剂23vPPV的原住民成人(N=20)、接受首剂23vPPV的原住民成人(N=60)和非原住民成人(N=25)。
- 采用ELISA检测基线及接种后一个月所有23种疫苗血清型的特异性IgG。
主要发现
- 非原住民成人首剂23vPPV后全部达到 adequate 应答(25/25)。
- 原住民成人首剂23vPPV后 adequate 应答比例为88%(53/60),第二剂后为70%(14/20),差异未达统计学显著(p=0.05)。
- 原住民首剂与非原住民首剂在≥70%血清型阳性应答阈值上风险差为-27%(95%CI:-43%至-11%;p=0.01)。
- 原住民首剂与非原住民首剂在≥90%血清型阳性应答阈值上风险差为-38%(95%CI:-60%至-16%;p=0.006)。
关键数值与推荐
- adequate 免疫应答定义为:配对血清抗体浓度4倍升高;或接种后抗体>1.3μg/ml但<4.0μg/ml时2倍升高;或接种后抗体浓度>4.0μg/ml的血清型至少半数(12/23)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Indigenous adults residing in the Northern Territory of Australia experience elevated rates of invasive pneumococcal disease despite the routine use of 23-valent pneumococcal polysaccharide vaccine (23vPPV). We hypothesised that the limited protection from 23vPPV may be due to hyporesponsiveness as a result of vaccine failure from repeated vaccination. To explore this possibility, we evaluated the immune response to a first and second dose of 23vPPV in Indigenous adults and a first dose of 23vPPV in non-Indigenous adults. METHODS: Serotype-specific IgG was measured by ELISA for all 23 vaccine serotypes at baseline and at one month post-vaccination. Individuals were considered to have an adequate immune response if paired sera demonstrated either: a four-fold rise in antibody concentration; a two-fold rise if the post vaccination antibody was >1.3μg/ml but <4.0μg/ml; or a post-vaccination antibody concentration >4.0μg/ml for at least half of the serotypes tested (12/23). Our per-protocol analysis included the comparison of outcomes for three groups: Indigenous adults receiving a second 23vPPV dose (N=20) and Indigenous (N=60) and non-Indigenous adults (N=25) receiving their first 23vPPV dose. RESULTS: All non-Indigenous adults receiving a first dose of 23vPPV mounted an adequate immune response (25/25). There was no significant difference in the proportion of individuals with an adequate response using our definition (primary endpoint), with 88% of Indigenous adults mounted an adequate response following first dose 23vPPV (53/60) compared to 70% having an adequate response following a second dose of 23vPPV (14/20; p=0.05). The risk difference between Indigenous participants receiving first dose compared to non-Indigenous participants receiving first dose was significant when comparing a response threshold of at least 70% (-27%, 95% CI: -43% to -11%; p=0.01) and 90% (-38%, 95% CI: -60% to -16%; p=0.006) of serotypes with a positive response. CONCLUSION: Indigenous participants demonstrated a poorer response to a first dose 23vPPV compared to their non-Indigenous counterparts, with lower IgG following a second 23vPPV dose. These findings highlight the critical need to evaluate the efficacy of future pneumococcal vaccine programs in the Australian Indigenous populations that recommend repeated doses of 23vPPV.
引用
- Moberley S, Licciardi PV, Balloch A, et al. Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness. Vaccine. 2017. PMID: 28455171. doi:10.1016/j.vaccine.2017.04.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。